ASCO 2023 | Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumors

Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, compares the real-world data of belzutifan in VHL-associated tumors versus clinical trial data. The objective response rate (ORR) for associated renal cell cancer was 23%, lower than the clinical trial’s 49%, likely due to shorter follow-up duration (8 months vs. 21 months) and less frequent scans. Safety findings were similar, with common side effects being anemia and fatigue (65-70%). Belzutifan dose was decreased in 30% of our patients (vs. 15% in the clinical trial) due to poorer performance status (ECOG 1-2 vs. ECOG 0). These results highlight the importance of longer follow-up and more frequent scans to capture treatment responses accurately in the real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.